Does the B-vitamin riboflavin lower blood pressure in individuals with high blood pressure who have a specific genetic make up?

An interventional study to investigate the effect of riboflavin supplementation (1.6mg/d/16weeks) on blood pressure in hypertensive individuals who are homozygous for the 677Câ T polymorphism (TT genotype) in the gene encoding the enzyme methylenetetrahydrofolate reductase (MTHFR)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN23620802

Enrollment

Registered

2012-02-02

Start date

2010-05-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension Circulatory System Essential (primary) hypertension

Interventions

Double-blind randomised controlled riboflavin (1.6mg/d/16 weeks) placebo-controlled trial in hypertensive individuals with the TT genotype

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Individuals recruited previously who consented to being contacted regarding future studies 2. Individuals identified as having the TT genotype

Exclusion criteria

Exclusion criteria: 1. A history of gastrointestinal, hepatic, renal or haematological disorders 2. Are taking B vitamin supplements, anticonvulsant therapy or any other drugs known to interfere with folate / B vitamin metabolism

Design outcomes

Primary

Measure	Time frame
Blood pressure	—

Secondary

Measure	Time frame
Riboflavin status	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 23, 2026